10x Genomics, Inc. (NASDAQ:TXG) Shares Bought by Perigon Wealth Management LLC

Perigon Wealth Management LLC boosted its position in 10x Genomics, Inc. (NASDAQ:TXG) by 23.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 9,656 shares of the company’s stock after purchasing an additional 1,818 shares during the quarter. Perigon Wealth Management LLC’s holdings in 10x Genomics were worth $540,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently bought and sold shares of the company. Raymond James & Associates boosted its holdings in shares of 10x Genomics by 19.3% in the 1st quarter. Raymond James & Associates now owns 53,009 shares of the company’s stock valued at $4,032,000 after purchasing an additional 8,570 shares during the last quarter. US Bancorp DE increased its stake in 10x Genomics by 39.6% during the 1st quarter. US Bancorp DE now owns 9,711 shares of the company’s stock worth $739,000 after buying an additional 2,753 shares during the period. PNC Financial Services Group Inc. lifted its stake in shares of 10x Genomics by 617.9% in the first quarter. PNC Financial Services Group Inc. now owns 2,046 shares of the company’s stock worth $155,000 after acquiring an additional 1,761 shares in the last quarter. MetLife Investment Management LLC purchased a new position in shares of 10x Genomics during the 1st quarter valued at approximately $416,000. Finally, BlackRock Inc. grew its holdings in 10x Genomics by 14.2% during the 1st quarter. BlackRock Inc. now owns 9,156,992 shares of the company’s stock worth $696,572,000 after acquiring an additional 1,138,358 shares in the last quarter. Institutional investors and hedge funds own 84.68% of the company’s stock.

10x Genomics Trading Down 4.9 %

Shares of TXG stock opened at $32.86 on Tuesday. The stock has a 50 day moving average of $41.22 and a two-hundred day moving average of $43.28. The company has a market capitalization of $3.92 billion, a P/E ratio of -15.14 and a beta of 1.90. 10x Genomics, Inc. has a 12 month low of $32.68 and a 12 month high of $63.57.

10x Genomics (NASDAQ:TXG) last announced its earnings results on Thursday, February 15th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.05). 10x Genomics had a negative return on equity of 28.82% and a negative net margin of 41.17%. The business had revenue of $183.98 million during the quarter, compared to analyst estimates of $182.73 million. During the same period in the previous year, the firm earned ($0.15) earnings per share. The firm’s revenue was up 17.8% compared to the same quarter last year. Sell-side analysts predict that 10x Genomics, Inc. will post -1.47 earnings per share for the current fiscal year.

Insider Transactions at 10x Genomics

In related news, CEO Serge Saxonov sold 4,660 shares of the company’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $44.00, for a total transaction of $205,040.00. Following the sale, the chief executive officer now owns 842,900 shares in the company, valued at $37,087,600. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CEO Serge Saxonov sold 4,660 shares of the business’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $44.00, for a total value of $205,040.00. Following the completion of the sale, the chief executive officer now directly owns 842,900 shares in the company, valued at approximately $37,087,600. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Benjamin J. Hindson sold 2,613 shares of the firm’s stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $46.34, for a total transaction of $121,086.42. Following the transaction, the insider now directly owns 283,059 shares in the company, valued at $13,116,954.06. The disclosure for this sale can be found here. Insiders have sold 12,959 shares of company stock worth $592,806 in the last three months. Insiders own 10.65% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Barclays lowered their price objective on shares of 10x Genomics from $55.00 to $45.00 and set an “overweight” rating for the company in a research report on Wednesday, April 10th. Stifel Nicolaus dropped their price target on shares of 10x Genomics from $68.00 to $63.00 and set a “buy” rating on the stock in a research report on Friday, February 16th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $60.88.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.